Funded Tech Companies

Aeglea BioTherapeutics

Aeglea BioTherapeutics, operating out of Austin, raised money from Lilly Ventures, Novartis Venture Fund and Ally Bridge Group.

Company Overview

Contact Information

Company Background Information

Overview

Aeglea BioTherapeutics (NASDAQ: AGLE) is developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

4/7/2016

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Anthony Quinn

        

Chief Financial Officer

Charles York

        

Chief Medical Officer

James Wooldridge

        

Chief Operating Officer

Leslie Sloan

        

VP - R & D

Scott Rowlinson

        

Company Investors

• Lilly Ventures (Armen Shanafelt)
• Novartis Venture Fund (Henry Skinner)
• Ally Bridge Group
• Cowen Capital Partners
• Venrock
• Rock Springs Capital
• RA Capital (Rajeev Shah)
• UT Horizon Fund
• KBI Biopharma

Browse more funded tech companies:

Aegle Therapeutics | Aelita Software

Share this article

About Our VC Deals Database

This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary